Results 131 to 140 of about 964 (170)

Olodaterol for the treatment of chronic obstructive pulmonary disease

American Journal of Health-System Pharmacy, 2016
Published data on the pharmacology, pharmacokinetics, efficacy, and safety of the once-daily, long-acting β2-agonist (LABA) olodaterol are reviewed.Olodaterol (Striverdi Respimat, Boehringer Ingelheim), a LABA with high selectivity for β2-adrenergic receptors, is indicated for the treatment of chronic obstructive pulmonary disease (COPD); the ...
Ramadan, Wijdan H., Kabbara, Wissam K., Abilmona, Rosa M.   +2 more
openaire   +3 more sources

▼Olodaterol—another LABA for COPD

Drug and Therapeutics Bulletin, 2015
▼Olodaterol solution for inhalation (Striverdi Respimat—Boehringer Ingelheim) is a long-acting beta2 agonist (LABA) licensed for once-daily use as maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). This is the third LABA to be licensed in the UK for once-daily use for patients with COPD. DTB has previously reviewed the
openaire   +2 more sources

Effect of olodaterol on the relaxation of small airways

European Respiratory Journal, 2011
Olodaterol (Ol) is a novel, selective, β 2 -agonist which offers bronchoprotection in mild asthmatics with duration of action of at least 24h. Small airways are the major site of obstruction in patients with COPD.
Stephanie M. Brown, Peter J. Barnes, Louise E. Donnelly   +2 more
openaire   +1 more source

Tiotropium/Olodaterol: A Review in COPD

Drugs, 2015
Tiotropium/olodaterol (Stiolto™ Respimat®, Spiolto™ Respimat®) is a fixed-dose combination of the long-acting antimuscarinic agent tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenoreceptor agonist olodaterol delivered via the Respimat® Soft Mist™ inhaler.
openaire   +2 more sources

Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review

Expert Opinion on Pharmacotherapy, 2018
Inhaled bronchodilators are the key-stone of chronic obstructive pulmonary disease (COPD) management. Olodaterol 5 µg, a long-acting β2-adrenoceptor agonist (LABA) is one such bronchodilator indicated as a once-daily maintenance therapy. Areas covered: This article reviews the several trials that have assessed olodaterol as a COPD therapy.
Andrea Melani
exaly   +3 more sources

Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease

Expert Review of Clinical Pharmacology, 2015
A solid scientific rationale and an increasing body of clinical evidence for combining a β2-agonist with an antimuscarinic agent in COPD fully support the opinion that patients not controlled by a single bronchodilator should be given two bronchodilators with different mechanisms of action.
CAZZOLA, MARIO, ROGLIANI, PAOLA, Ora, J, Matera, Mg   +3 more
openaire   +5 more sources

Interaction between tiotropium bromide and olodaterol in small human airways

Airway Pharmacology and Treatment, 2017
Background: Combining a long-acting β2-agonist (LABA) with a long-acting muscarinic antagonist (LAMA) may improve chronic obstructive pulmonary disease therapy. Aim: We investigated the pharmacological interaction of tiotropium bromide (LAMA) and olodaterol (LABA) in small human bronchi.
Calzetta L, Rogliani P, Facciolo F, Matera MG, Cazzola M   +4 more
openaire   +2 more sources

Olodaterol attenuates bleomycin induced lung fibrosis in mice

5.1 Airway Pharmacology and Treatment, 2016
Background: The long-acting β 2 -agonist (LABA) olodaterol was shown to have anti-fibrotic activity in primary human lung fibroblasts (Herrmann et al, Eur Respir J. 2014;44:Suppl.58) however, its anti-fibrotic in vivo efficacy has not yet been demonstrated. Aim: To test the effect of olodaterol in a mouse model of bleomycin induced lung fibrosis.
Franziska Herrmann, Stefan-Lutz Wollin, Florian Gantner, Eva Wex   +3 more
openaire   +1 more source

Olodaterol: Once-daily inhalation spray for COPD

Pharmacy Today, 2014
FDA has approved olodaterol (Striverdi Respimat—Boehringer Ingelheim), a once-daily inhalation spray to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The long-acting beta-adrenergic agonist (LABA), delivered via a propellant-free inhaler, helps the muscles around ...
openaire   +1 more source

Functional and Biochemical Rationales for the 24-Hour-Long Duration of Action of Olodaterol

The Journal of Pharmacology and Experimental Therapeutics, 2011
β(2)-Adrenoceptor (β(2)-AR) agonists are powerful bronchodilators and play a pivotal role in the management of pulmonary obstructive diseases, such as asthma and chronic obstructive pulmonary disease. Although these agents first were used many years ago, progress in drug development has resulted in better tolerated, long-acting β(2)-AR agonists (LABAs),
Paola, Casarosa, Ines, Kollak, Tobias, Kiechle, Angela, Ostermann, Andreas, Schnapp, Ralf, Kiesling, Michael, Pieper, Peter, Sieger, Florian, Gantner   +8 more
openaire   +2 more sources